Stella Pharma Corporation
2nd Quarter Financial Results Presentation
Interim sales decreased 12.5% year-over-year to 175 million yen. Selling, general and administrative expenses increased mainly due to production transfer-related costs, resulting in an operating loss of -498 million yen, ordinary loss of -467 million yen, and interim net loss of -469 million yen. Full-year outlook unchanged for now: sales 1,038 million yen, operating loss -696 million yen, interim net loss -628 million yen. Capital policy explained to invest approximately 4.2 billion yen into six growth themes.
Key Figures
- Sales: 175 million yen (YoY -12.5%), 2Q
- SG&A: 643.6 million yen, YoY +178.9 million yen
- Operating Income: -498 million yen
- Interim Net Income: -469 million yen
- Subsidy Income: 53 million yen (recorded as non-operating income)
AI要約
Performance Overview
In the interim period, sales decreased 12.5% year-over-year. Although the gross profit margin was maintained at the same level as the previous period, SG&A expenses increased significantly mainly due to higher production transfer-related costs. As a result, operating income, ordinary income and interim net income were in deficit. Subsidy income of 53 million yen was recorded as non-operating income, partially offsetting the ordinary loss and net loss.
Full-Year Outlook and Capital Policy
For the full year, the company forecasts sales of 1,038 million yen, operating loss of -696 million yen, ordinary loss of -625 million yen, and interim net loss of -628 million yen. As a medium-term growth strategy, approximately 4.2 billion yen will be invested across six growth themes (expansion of new businesses, broadened indications, overseas expansion, market development, talent acquisition, etc.), promoting reconstruction of the supply base and regional deployment centered on the BNCT business.
Stella Pharma Corporation
Company overview · Stock price · Financial data · All IR